Targeted Delivery in Pancreatic Cancer
Author Information
Author(s): Khan Jameel Ahmad, Kudgus Rachel A., Szabolcs Annamaria, Dutta Shamit, Wang Enfeng, Cao Sheng, Curran Geoffry L., Shah Vijay, Curley Steven, Mukhopadhyay Debabrata, Robertson J. David, Bhattacharya Resham, Mukherjee Priyabrata
Primary Institution: Mayo Clinic, Rochester, Minnesota, United States of America
Hypothesis
What are the design criteria for fabricating nanoconjugates that will ensure maximum uptake in cancer cells?
Conclusion
The study suggests that specific targeting of tumor cells depends on several critical components including the targeting agent to nanoparticle ratio and the hydrodynamic diameter of the nanoconjugate.
Supporting Evidence
- Gold nanoparticles can non-invasively kill tumor cells by hyperthermia using radiofrequency.
- The study shows that the number of cetuximab molecules on a GNP plays a critical role in targeting tumor cells.
- The hydrodynamic size of the nanoconjugates affects their ability to sequester EGFR.
Takeaway
This study is about using tiny gold particles to deliver medicine directly to pancreatic cancer cells, making treatment more effective.
Methodology
The study characterized nanoconjugates using various physico-chemical techniques and tested their targeting ability in vitro and in vivo.
Limitations
The study primarily focuses on specific ratios of antibodies to nanoparticles and may not account for all variables in tumor microenvironments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website